Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience

Basit Öğe Kaydı
dc.contributor.authorTas Ozyurtseven, Betul
dc.contributor.authorSerin, Istemi
dc.contributor.authorNursal, Ayse Feyda
dc.contributor.authorPehlivan, Sacide
dc.contributor.authorPehlivan, Mustafa
dc.date.accessioned2021-11-01T15:05:58Z
dc.date.available2021-11-01T15:05:58Z
dc.date.issued2021
dc.department[Belirlenecek]
dc.description.abstractBackground Multiple myeloma (MM) constitutes approximately 10% of hematological malignancies. Bisphosphonates have established themselves in solid organ metastasis and multiple myeloma lytic bone lesions by inhibiting osteoclast activation. Medication-related osteonecrosis of the jaw (MRONJ) emerges as an important complication. Investigating host-based factors, and developing personal risk factors gain importance in the development mechanism of MRONJ. We aimed to reveal the different genotype polymorphisms, and clinical effects of eNOS in patients with a diagnosis of MRONJ in MM patients. Methods Medical records and blood samples were collected from 60 MRONJ patients with MM and 60 healthy controls. Inclusion criteria was having an exposed maxillofacial bone for more than eight weeks, a history of bisphosphonates, and no history of radiation therapy for the jaws. eNOS G894T and intron 4 VNTR were calculated by polymerase chain reaction and/or restriction fragment length polymorphism. Results eNOS G894T and VNTR genotypes and alleles were compared statistically with the healthy control group. There was no significant difference between the two groups. In comparison between G894T and clinical parameters, aphthous stomatitis was more common in TT genotype, while DMFT > 3 was more common in TG-GG genotype (p = 0.035, 0.023). Conclusions eNOS induces osteogenesis in bone metabolism, with its regulatory effects on bone remodeling and also NO induced angiogenesis takes place indirectly with its protective effect on endothelial functions. We see that these polymorphisms affecting the entire process of bone remodeling and angiogenesis, especially mucosal damage, which is the triggering factor of MRONJ pathology, have been revealed in the MM patient group. Considering the MRONJ initiating factors, it is necessary to emphasize the importance of our study results. It should be seen as an important step for new studies towards MRONJ and its treatment.
dc.identifier.doi10.1186/s12903-021-01634-9
dc.identifier.issn1472-6831
dc.identifier.issue1en_US
dc.identifier.pmid34006261
dc.identifier.scopus2-s2.0-85106200317
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1186/s12903-021-01634-9
dc.identifier.urihttps://hdl.handle.net/11491/7456
dc.identifier.volume21en_US
dc.identifier.wosWOS:000657681500002
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofBmc Oral Health
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMedication-related osteonecrosis of the jaws (MRONJ)en_US
dc.subjectBisphosphonateen_US
dc.subjectMultiple myelomaen_US
dc.subjectEndothelial nitric oxide synthaseen_US
dc.titleMedication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu